


**A FACILE SYNTHESIS OF TUBERCIDIN AND RELATED 7-DEAZAPURINE NUCLEOSIDES
VIA THE STEREOSPECIFIC SODIUM SALT GLYCOSYLATION PROCEDURE**

Kandasamy Ramasamy, Nobutaka Imamura, Roland K. Robins and Ganapathi R. Revankar*

Department of Medicinal Chemistry, Nucleic Acid Research Institute,
3300 Hyland Avenue, Costa Mesa, California 92626, U.S.A.


Summary. A facile high-yield synthesis of 7-deazaadenosine (tubercidin, 5), 7-deazaguanosine (10), 2'-deoxy-7-deaza-6-thioguanosine (12) and 2'-deoxy-7-deazaguanosine (15) by the regioselective and stereospecific sodium salt glycosylation procedure is described.

Since the isolation¹⁻³ and structural elucidation⁴ of the naturally occurring pyrrolo[2,3-d]pyrimidine nucleoside antibiotics tubercidin (5), toyocamycin and sangivamycin derived from *Streptomyces* species, a number of reports have appeared in the literature describing their biological (antiviral, antineoplastic and antiparasitic) and physicochemical properties.⁵⁻⁸ In addition, the base- as well as the sugar-modified analogues of these natural nucleosides have been prepared and evaluated for their antiviral and antitumor activities.⁹⁻¹¹ Notwithstanding the several multistep synthesis of 5 and related compounds reported so far,^{4,12} there is still a need for a simple and straightforward large-scale preparation of these antibiotics and their derivatives. We now report a facile and high-yield route to tubercidin (5) by the sodium salt glycosylation procedure¹³ and also demonstrate the potential of this procedure for the improved synthesis of 7-deazaguanosine (10) as well as 2'-deoxy-7-deazaguanosine (15).



Our strategy was to accomplish the regiocontrolled and stereospecific glycosylation of the sodium salt of 4-chloro- and 2-amino-4-chloropyrrolo[2,3-d]pyrimidine (1 or 6, respectively) with an appropriate halogenose to obtain the protected nucleoside intermediate, which could then be converted to the desired 5, 10 or 15. As a representative example, the sodium salt of 4-chloropyrrolo[2,3-d]pyrimidine¹⁴ (1, 20 mmol), generated in situ by the treatment with sodium hydride (60% in oil, 20 mmol), in anhydrous acetonitrile, was reacted with 1-chloro-2,3-O-isopropylidene-5-O-t-butylidimethylsilyl- α -D-ribofuranose¹⁵ (2, 10 mmol), at ambient temperature for 1 hour in a dry inert atmosphere. The reaction mixture was filtered to remove

a small amount of insoluble material. Evaporation of the filtrate and purification of the residue on a flash silica gel column using hexane:ethyl acetate (9:1, v/v) as the solvent, gave syrupy 4-chloro-7-(2,3-*O*-isopropylidene-5-*O*-*t*-butyldimethylsilyl- β -D-ribofuranosyl)-pyrrolo[2,3-*d*]pyrimidine¹⁶ (**3**, 67% yield). Compound **3** was the only nucleoside product which could be detected by TLC or column chromatography procedures. Deprotection of **3** with 90% aqueous trifluoroacetic acid at room temperature for 1 hour furnished 4-chloro-7- β -D-ribofuranosylpyrrolo[2,3-*d*]pyrimidine (**4**) [98.5% yield; mp 161-163°C (Lit.¹⁷ mp 161-163°C)]. Treatment of **4** with methanolic ammonia (saturated at 0°C) at 120°C for 15 hours resulted in the displacement of the chloro group to provide 4-amino-7- β -D-ribofuranosylpyrrolo[2,3-*d*]pyrimidine (tubercidin, **5**; 81% yield) with mp 248-250°C [Lit.⁵ mp 247-248°C].¹⁸ There was no depression observed by mixture melting point of an authentic sample.¹⁹



Extrapolation of this regioselective and stereospecific glycosylation procedure also makes it an eminently attractive method for the synthesis of guanosine analogues in the 7-deazapurine ring system. Thus, treatment of 2-amino-4-chloro-7H-pyrrolo[2,3-*d*]pyrimidine²⁰ (**6**, 6 mmol) with sodium hydride (6 mmol) in acetonitrile, followed by the addition of **2** (6 mmol) and subsequent purification of the reaction product by flash chromatography on a column of silica gel (hexane:ethyl acetate, 9:1, v/v) provided syrupy **7** (53% yield).¹⁶ Further treatment of **7** with 1N sodium methoxide in methanol at reflux temperature for 8 hours gave a 83% yield of 2-amino-4-methoxy-7-(2,3-*O*-isopropylidene- β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (**8**),¹⁶ which on deisopropylideneation with aqueous trifluoroacetic acid at ambient temperature for 0.5 hour and purification of the product on a column of silica gel (dichloromethane:acetone, 1:1, v/v) furnished 2-amino-4-methoxy-7- β -D-ribofuranosylpyrrolo[2,3-*d*]pyrimidine [**9**, 92% yield, mp 247-250°C]. Cleavage of the ether-linkage of **9** with trimethylsilyl iodide²¹ in anhydrous acetonitrile at reflux temperature for 9 hours gave 2-amino-7- β -D-ribofuranosylpyrrolo[2,3-*d*]pyrimidin-4(3H)-one (**10**, mp 312-314°C, 90% yield), which was shown to be identical with 7-deazaguanosine as previously reported.²²

This general procedure was also utilized to prepare 2'-deoxy-7-deazaguanosine (15). The sodium salt of 6 (3 mmol), produced in situ by sodium hydride in acetonitrile, was treated with 1-chloro-2-deoxy-3,5-di-O-p-toluoyl- α -D-erythro-pentofuranose²³ (11, 3.3 mmol) at ambient temperature for 16 hours. After purification of the reaction product on a silica gel column (chloroform:ethyl acetate, 9:1, v/v), a 75% yield of 13 was obtained (mp 162-164°C), which is significantly superior to the 45% yield reported by the strongly alkaline conditions of phase-transfer procedure.²⁰ No formation of the α -anomer of 13 in this reaction was detected. When 13 was treated with 0.5N sodium methoxide in methanol at reflux temperature for 1 hour, deprotection of the sugar moiety with concomitant nucleophilic displacement of the 4-chloro function to a methoxy group occurred to give 2-amino-4-methoxy-7-(2-deoxy- β -D-erythro-pentofuranosyl)pyrrolo[2,3-d]pyrimidine [14, yield 92%, mp 152-154°C (Lit.²⁴ mp 152-154°C)]. Treatment of 14 with trimethylsilyl iodide gave a 92% yield of 7-deaza-2'-deoxyguanosine [15, mp 264-266°C, (Lit.²⁴ mp 262-265°C)]. Compound 15 was also obtained, in 15% yield, from 2'-deoxy-7-deaza-6-thioguanosine (12) by oxidative hydrolysis (ammonium hydroxide/hydrogen peroxide). 2'-Deoxy-7-deaza-6-thioguanosine [mp 196-201°C, dec; 72% yield, (Lit.²⁰ mp >200°C)] was, in turn, prepared from 13 by treatment with thiourea in the presence of formic acid, followed by deprotection with sodium methoxide in methanol.

The anomeric configuration of the isolated pyrrolo[2,3-d]pyrimidine nucleosides was assigned as β on the basis of ¹H NMR studies. The ¹H NMR spectra of 4 and 9 in Me₂SO-d₆ revealed the anomeric doublets centered at δ 6.20 and 5.96, respectively, with a coupling constant $J_{1,2} = 6.0$ Hz, which is within the acceptable limits for β -ribonucleosides.^{25,26} Moreover, the ¹H NMR spectra of 3 and 8 in Me₂SO-d₆ exhibited much smaller coupling constants ($J_{1,2} = 3.0$ Hz) and also revealed the difference between the chemical shift of the two methyl signals of the isopropylidene group as >0.20 ppm, a difference characteristic of the β -configuration.²⁷ The anomeric configuration of 13 was also assigned as β by ¹H NMR studies, where the anomeric proton was observed as dd at δ 6.58 with a peak width of 14 Hz. This pattern is similar to that observed for the anomeric proton of 2'-deoxy-7-deazaguanosine.²⁴ Since the starting halogenose 11 has the α -configuration²⁸ in the solid state, the exclusive formation of 13 is presumed to be due to a direct Walden inversion (S_N2) at the C₁ carbon by the anionic heterocyclic nitrogen.

Thus, the facile synthetic pathway we have developed for the total synthesis of tubercidin, 7-deazaguanosine and 2'-deoxy-7-deazaguanosine can now be used for gram-scale preparation of these nucleoside derivatives. This procedure, starting with an appropriate aglycon and a suitable halogenose, appears to be superior to the previously reported glycosylations of this ring system^{4,29,30} including the phase-transfer procedure.^{20,22}

REFERENCES AND NOTES

1. H. Nishimura, K. Katagiri, K. Sato, M. Mayama and N. Shimaoka, *J. Antibiot.*, **9A**, 60 (1956).
2. K. Anzai, G. Nakamura and S. Suzuki, *J. Antibiot.*, **10A**, 201 (1957).
3. K.V. Rao and D.W. Renn, *Antimicrob. Agents Chemother.*, **77** (1963).
4. R.L. Tolman, R.K. Robins and L.B. Townsend, *J. Am. Chem. Soc.*, **91**, 2102 (1969).
5. R.J. Suhadolnik, "Nucleoside Antibiotics", Wiley-Interscience, New York (1970), pp 298-389.

6. R.J. Suhadolnik, "Nucleosides as Biological Probes", Wiley-Interscience, New York, (1979), pp 158-169.
7. P.S. Ritch and R.I. Glazer, "Developments in Cancer Chemotherapy", R.I. Glazer, Ed., CRC Press, Inc., Ohio, (1984), pp 1-33.
8. R.K. Robins and G.R. Revankar, Med. Res. Reviews, 5, 273 (1985).
9. G.R. Revankar and R.K. Robins, in "Chemistry of Nucleosides and Nucleotides", L.B. Townsend, Ed., Plenum Press, New York, in press.
10. E. DeClercq, J. Balzarini, D. Madej, F. Hansske and M.J. Robins, J. Med. Chem., 30, 481 (1987).
11. K. Ramasamy, R.K. Robins and G.R. Revankar, Tetrahedron, 42, 5869 (1986).
12. F. Seela, H-D. Winkeler, J. Ott, Q-H. Tran-Thi, D. Hasselmann, D. Franzen and W. Bussman, in "Nucleosides, Nucleotides, and their Biological Applications", J.L. Rideout, D.W. Henry and L.M. Beacham III, Eds, Academic Press, Inc., New York, (1983), pp 181-208.
13. Z. Kazimierczuk, H.B. Cottam, G.R. Revankar and R.K. Robins, J. Am. Chem. Soc., 106, 6379 (1984).
14. J. Davoll, J. Chem. Soc., 131 (1960).
15. C.S. Wilcox and R.M. Otoski, Tetrahedron Lett., 27, 1011 (1986).
16. Satisfactory spectral data and elemental analyses were obtained for all the new compounds isolated.
17. J.F. Gerster, B. Carpenter, R.K. Robins and L.B. Townsend, J. Med. Chem., 10, 326 (1967).
18. Compound 5 was found to possess the same ultraviolet, infrared and ^1H NMR spectra, and identical R_f values in three different chromatographic solvent systems as naturally occurring tubercidin.
19. Authentic sample of tubercidin was purchased from the Upjohn Co., Kalamazoo, MI, U.S.A.
20. F. Seela, H. Steker, H. Driller and U. Bindig, Liebigs Ann. Chem., 15 (1987).
21. G.A. Olah, S.C. Narang, B.G.B. Gupta and R. Malhotra, J. Org. Chem., 44, 1247 (1979).
22. F. Seela and D. Hasselmann, Chem. Ber., 114, 3395 (1981).
23. M. Hoffer, Chem. Ber., 93, 2777 (1960).
24. H-D. Winkeler and F. Seela, J. Org. Chem., 48, 3119 (1983).
25. N.J. Leonard and R.A. Laursen, J. Am. Chem. Soc., 85, 2026 (1963).
26. L.B. Townsend, Synth. Proced. Nucleic Acid Chem., 2, 331 (1973).
27. J-L. Imbach, J-L. Barascut, B.L. Kam, B. Rayner, C. Tamby and C. Tapiero, J. Heterocycl. Chem., 10, 1069 (1973).
28. A.K. Bhattacharya, R.K. Ness and H.G. Fletcher, Jr., J. Org. Chem., 28, 428 (1963).
29. R.L. Tolman, G.L. Tolman, R.K. Robins and L.B. Townsend, J. Heterocycl. Chem., 7, 799 (1970).
30. L.B. Townsend, R.L. Tolman, R.K. Robins and G.H. Milne, J. Heterocycl. Chem., 13, 1363 (1976).

(Received in USA 26 June 1987)